Pipeline
A pipeline of powerful possibilities.
Our dynamic portfolio of virology assets includes a pipeline focused on curing HBV and treating coronavirus infections. Today, we have several active preclinical studies and clinical trials in these therapeutic areas, including approaches combining different mechanisms of action to achieve our therapeutic goals.

Lead Optimization
IND Enabling
Phase 1
Phase 2
Phase 3
Marketed
HBV
RNAi Therapeutic AB-729
PD-L1 Inhibitor (oral) AB-101
RNA destabilizer (oral) AB-161
COVID-19
Mpro inhibitor (oral) AB-343
nsp12 polymerase inhibitor (oral)
All Arbutus clinical trials are conducted in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice

Coronavirus
Learn more about how we are innovating in pan-coronavirus treatment.